LZRSE-Col7A1 Engineered Autologous Epidermal Sheets ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 36 | Epidermolysis bullosa | 1 |
36. Epidermolysis bullosa
Clinical trials : 160 / Drugs : 195 - (DrugBank : 47) / Drug target genes : 50 - Drug target pathways : 124
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01263379 (ClinicalTrials.gov) | October 5, 2010 | 15/12/2010 | Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa | A Phase 1/2A Single Center Trial of Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Using the Drug LZRSE-Col7A1 Engineered Autologous Epidermal Sheets (LEAES) | Epidermolysis Bullosa Dystrophica;Epidermolysis Bullosa | Biological: LZRSE-Col7A1 Engineered Autologous Epidermal Sheets | Stanford University | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);Abeona Therapeutics, Inc | Active, not recruiting | 13 Years | N/A | All | 10 | Phase 1/Phase 2 | United States |